Clinical Trials Logo
  1. Home
  2. Raynaud's Disease
  3. NCT00528242

Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease

Raynaud's Disease Clinical Trial

Official title:
A Randomized, Double Blind, Placebo-controlled, Cross-over Pilot Study to Examine the Safety, Tolerability and Pharmacodynamic Profile of Repeat Oral Doses of SLx-2101 Once Daily for up to 14 Days in Subjects With Secondary Raynaud's Disease.

Clinical Trial Summary

To investigate the severity of secondary Raynaud's disease-related attacks during the 14 days 2101 dosing period.

Clinical Trial Description

1. Number and cumulative duration of Raynaud's attacks. 2. Adverse events and changes in vital signs. 3. SLx-2101 pharmacokinetic parameters derived after dosing on Day 1 and Day maximum plasma concentration (Cmax), area under the plasma concentration-time curve (AUC0-4), time to Cmax (tmax), and accumulation ratio ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00528242
Study type Interventional
Source Response Pharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date June 2007
Completion date March 2008
View Details
See also
  Status Clinical Trial Phase
Completed NCT00000530 - Raynaud's Treatment Study (RTS) Phase 3
Completed NCT00048763 - Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Phase 4
Completed NCT00048776 - Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Phase 4
Enrolling by invitation NCT02615964 - Nova Cold Hands Raynaud's Disorder, a Disease Which Results in Decreased Blood Flow to the Hands and Feet. N/A
Completed NCT01309802 - A Two-Part Study of BOTOX® Therapy for Ischemic Digits Phase 2
Completed NCT00480753 - Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon Phase 2
Completed NCT02396238 - Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR) N/A
Completed NCT00351117 - St. John's Wort in the Treatment of Raynaud's Phenomenon Phase 3
Completed NCT00378521 - Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon Phase 2
Completed NCT02683408 - Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon N/A
Active, not recruiting NCT00577304 - A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon Phase 3
Completed NCT00419419 - Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon Phase 3
Completed NCT00266669 - Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon Phase 3
Completed NCT01090492 - PF-00489791 For The Treatment Of Raynaud's Phase 2